> There is a clear medical need for better diabetes treatments and a large profitable market for anyone who can deliver them. True, but with the exception of t

> There is a clear medical need for better diabetes treatments and a large profitable market for anyone who can deliver them. True, but with the exception of type I diabetics (a relatively small proportion of all diabetics, about 3% of total), the goal is to avoid insulin treatment. What you want to do is reverse insulin resistance, while restoring blood glucose control. Basically reverse metabolic syndrome. That's what the therapies like SGLT2 inhibitors, GLP1s, DPP-4 inhibitors, etc. If a type II patient gets to the point of needing exogenous insulin, you've basically reached the end of the line.